RxDoctor Payments Data

Lisa Ronning, PA

Physician Assistant · Brighton, MANPI 1528711850

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 49 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$243
  • Novo Nordisk$170
  • AbbVie$121
  • Abbott$115
  • Amgen$114
  • Xeris Pharmaceuticals, Inc.$62
  • plus $284 from 10 others

What the payments were for

  • Food & beverage$1,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,110 in reported general payments places this provider in the 85th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$54,674
Medicare patients
137
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide167$262,376
OzempicSemaglutide121$223,863
MounjaroTirzepatide117$184,467
JardianceEmpagliflozin153$175,439
RybelsusSemaglutide19$43,566
JanuviaSitagliptin Phosphate30$39,451
TradjentaLinagliptin27$32,124
Tresiba Flextouch U-100Insulin Degludec42$30,759
FarxigaDapagliflozin Propanediol22$29,288
Tresiba Flextouch U-200Insulin Degludec23$21,859
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$16,253
Humalog Kwikpen U-100Insulin Lispro35$12,703
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$12,577
Fiasp FlextouchInsulin Aspart (Niacinamide)11$9,391
Nano 2nd Gen Pen NeedlePen Needle, Diabetic67$6,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$243$446,843284 claims
Novo NordiskOzempic, Rybelsus$170$267,430140 claims
Boehringer IngelheimJardiance, Tradjenta$21$207,563180 claims
AstraZenecaFarxiga$53$29,28822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Brighton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →